Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FV9Z
|
|||
| Drug Name |
Pyrazolodihydropyridine derivative 1
|
|||
| Synonyms |
PMID27828716-Compound-13
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
THE BROAD INSTITUTE, INC. DANA-FARBER CANCER INSTITUE, INC. THE GENERAL HOSPITAL CORPORATION D/B/A
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H23N3O2
|
|||
| Canonical SMILES |
CC1=C2C(C3=C(CC(CC3=O)(C)C)NC2=NN1)C4=CC=CC=C4OC
|
|||
| InChI |
1S/C20H23N3O2/c1-11-16-17(12-7-5-6-8-15(12)25-4)18-13(21-19(16)23-22-11)9-20(2,3)10-14(18)24/h5-8,17H,9-10H2,1-4H3,(H2,21,22,23)/t17-/m0/s1
|
|||
| InChIKey |
KYFJPYWXCUCRPE-KRWDZBQOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Glycogen synthase kinase-3 alpha (GSK-3A) | Target's Patent Info | [1] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Insulin/IGF pathway-protein kinase B signaling cascade | ||||
| PDGF signaling pathway | ||||
| Ras Pathway | ||||
| Pathway Interaction Database | Degradation of beta catenin | |||
| Canonical Wnt signaling pathway | ||||
| FOXM1 transcription factor network | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| Reactome | AKT phosphorylates targets in the cytosol | |||
| XBP1(S) activates chaperone genes | ||||
| Constitutive Signaling by AKT1 E17K in Cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.